Cargando…

Epidemiology of mucopolysaccharidoses (MPS) in United States: challenges and opportunities

BACKGROUND: Mucopolysaccharidoses (MPS) are rare, inherited lysosomal storage disorders characterized by progressive multiorgan involvement. Previous studies on incidence and prevalence of MPS mainly focused on countries other than the United States (US), showing considerable variation by country. T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Puckett, Yana, Mallorga-Hernández, Alejandra, Montaño, Adriana M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164808/ https://www.ncbi.nlm.nih.gov/pubmed/34051828 http://dx.doi.org/10.1186/s13023-021-01880-8

Ejemplares similares

Critical clinical situations in adult patients with Mucopolysaccharidoses (MPS)
por: Stepien, Karolina M., et al.
Publicado: (2020)

Brain Pathology in Mucopolysaccharidoses (MPS) Patients with Neurological Forms
por: Viana, Gustavo M., et al.
Publicado: (2020)

Epidemiology of Mucopolysaccharidoses Update
por: Celik, Betul, et al.
Publicado: (2021)

Orthopaedic challenges for mucopolysaccharidoses
por: Borgo, Andrea, et al.
Publicado: (2018)

Establishment of Glycosaminoglycan Assays for Mucopolysaccharidoses
por: Tomatsu, Shunji, et al.
Publicado: (2014)

Glaucoma in mucopolysaccharidoses
por: Kong, Weijing, et al.
Publicado: (2021)

ENT and mucopolysaccharidoses
por: Bianchi, Pier Marco, et al.
Publicado: (2018)

Diagnosis of Mucopolysaccharidoses
por: Kubaski, Francyne, et al.
Publicado: (2020)

Gene Therapy for Neuronopathic Mucopolysaccharidoses: State of the Art
por: de Castro, María José, et al.
Publicado: (2021)

Evaluating strategies to manage and endure challenging behaviors in mucopolysaccharidoses
por: Grant, Nathan
Publicado: (2021)

Dyspnoea at rest predictor of increased in-hospital mortality in metastatic cancer patients undergoing emergent surgery in United States
por: Majdinasab, Elleana J, et al.
Publicado: (2020)

Pediatric Trauma Transfer Imaging Inefficiencies—Opportunities for Improvement with Cloud Technology
por: Puckett, Yana, et al.
Publicado: (2016)

Bone Biomarkers in Mucopolysaccharidoses
por: Nakamura-Utsunomiya, Akari
Publicado: (2021)

The new frame for Mucopolysaccharidoses
por: Parini, Rossella, et al.
Publicado: (2018)

Anesthesiological risks in mucopolysaccharidoses
por: Moretto, Alessandra, et al.
Publicado: (2018)

Newborn screening in mucopolysaccharidoses
por: Donati, Maria Alice, et al.
Publicado: (2018)

Pathogenesis of Mucopolysaccharidoses, an Update
por: Fecarotta, Simona, et al.
Publicado: (2020)

Ophthalmological Findings in Mucopolysaccharidoses
por: Tomatsu, Shizuka, et al.
Publicado: (2019)

Genome Editing for Mucopolysaccharidoses
por: Poletto, Edina, et al.
Publicado: (2020)

Atypical corneal clouding in mucopolysaccharidoses
por: Stephen, Mary, et al.
Publicado: (2023)

Leukocyte Imbalances in Mucopolysaccharidoses Patients
por: Lopes, Nuno, et al.
Publicado: (2023)

Establishing a core outcome set for mucopolysaccharidoses (MPS) in children: study protocol for a rapid literature review, candidate outcomes survey, and Delphi surveys
por: Howie, Alison H., et al.
Publicado: (2021)

Prevalence rates of mucopolysaccharidoses in Poland
por: Jurecka, Agnieszka, et al.
Publicado: (2014)

Neurobehavioral phenotypes of neuronopathic mucopolysaccharidoses
por: Barone, Rita, et al.
Publicado: (2018)

Correction to: Newborn screening in mucopolysaccharidoses
por: Donati, Maria Alice, et al.
Publicado: (2019)

Editorial: Molecular Aspects of Mucopolysaccharidoses
por: Węgrzyn, Grzegorz, et al.
Publicado: (2022)

Mucopolysaccharidoses and the blood–brain barrier
por: Sahin, Onur, et al.
Publicado: (2022)

Otorhinolaryngological Management in Taiwanese Patients with Mucopolysaccharidoses
por: Lee, Chung-Lin, et al.
Publicado: (2021)

Timing unit MPS 2051
por: Jamsek, J
Publicado: (1961)

Environmental epidemiology: challenges and opportunities.
por: Pekkanen, J, et al.
Publicado: (2001)

Correction to: Establishing a core outcome set for mucopolysaccharidoses (MPS) in children: study protocol for a rapid literature review, candidate outcomes survey, and Delphi surveys
por: Howie, Alison H., et al.
Publicado: (2021)

Pentosan Polysulfate: A Novel Therapy for the Mucopolysaccharidoses
por: Schuchman, Edward H., et al.
Publicado: (2013)

Foreign-Trained Dentists in the United States: Challenges and Opportunities
por: Kellesarian, Sergio Varela
Publicado: (2018)

Addition of MPS-II to the Recommended Uniform Screening Panel in the United States
por: Millington, David S., et al.
Publicado: (2022)

Oxidative Stress in Mucopolysaccharidoses: Pharmacological Implications
por: Pierzynowska, Karolina, et al.
Publicado: (2021)

Glycosaminoglycans as Biomarkers for Mucopolysaccharidoses and Other Disorders
por: Amendum, Paige C., et al.
Publicado: (2021)

Mucopolysaccharidoses type I gene therapy
por: Hurt, Sarah C., et al.
Publicado: (2021)

A CLINICAL AND BIOCHEMICAL STUDY OF THE MUCOPOLYSACCHARIDOSES
por: Narayanan, H.S., et al.
Publicado: (1987)

FUNCTIONAL INDEPENDENCE OF PEDIATRIC PATIENTS WITH MUCOPOLYSACCHARIDOSES
por: Lopes, Paloma Silva, et al.
Publicado: (2019)

Ophthalmologic manifestations in Taiwanese patients with mucopolysaccharidoses
por: Lin, Hsiang‐Yu, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_cts890f6m95n8brs458boljmkg